Gut hormones: Implications for the treatment of obesity
- 1 October 2009
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 124 (1) , 44-56
Abstract
No abstract availableKeywords
This publication has 195 references indexed in Scilit:
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008
- Caudal brainstem delivery of ghrelin induces fos expression in the nucleus of the solitary tract, but not in the arcuate or paraventricular nuclei of the hypothalamusBrain Research, 2008
- Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studiesProceedings of the National Academy of Sciences, 2008
- Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1Proceedings of the National Academy of Sciences, 2007
- Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanismNature, 2006
- Vaccination against weight gainProceedings of the National Academy of Sciences, 2006
- Interaction of Dietary composition and PYY gene expression in diet-induced obesity in ratsCurrent Medical Science, 2005
- Pharmacological Therapies for ObesityGastroenterology Clinics of North America, 2005
- Feeding response to ghrelin agonist and antagonist in lean and obese Zucker ratsLife Sciences, 2004
- Co-secretion of amylin and insulin from cultured islet β-cells: Modulation by nutrient secretagogues, islet hormones and hypoglycemic agentsBiochemical and Biophysical Research Communications, 1991